Page 29 - BH-1-2

Brain & Heart Pemafibrate in patients with dyslipidemia

17. Fruchart JC, 2017, Pemafibrate (K-877), a novel selective hypertriglyceridemia: A randomized, double-blind, placebo-
peroxisome proliferator-activated receptor alpha modulator controlled, phase 3 trial. Diabetes Care, 41: 538–546.
for management of atherogenic dyslipidaemia. Cardiovasc https://doi.org/10.2337/dc17-1589
Diabetol, 16: 124.
25. Ginsberg HN, Hounslow NJ, Senko Y, et al., 2022, Efficacy
https://doi.org/10.1186/s12933-017-0602-y and safety of K-877 (Pemafibrate), a selective PPARα
18. Das Pradhan A, Glynn RJ, Fruchart JC, et al., 2022, modulator, in European patients on statin therapy. Diabetes
Triglyceride lowering with pemafibrate to reduce Care, 45: 898–908.
cardiovascular risk. N Engl J Med, 387: 1923–1934. https://doi.org/10.2337/dc21-1288
https://doi.org/10.1056/NEJMoa2210645 26. Ishibashi S, Yamashita S, Arai H, et al., 2016, Effects of
19. Page MJ, McKenzie JE, Bossuyt PM, et al., 2021, The K-877, a novel selective PPARα modulator (SPPARMα),
PRISMA 2020 statement: An updated guideline for reporting in dyslipidaemic patients: A randomized, double blind,
systematic reviews. BMJ, 372: n71. active and placebo-controlled, phase 2 trial. Atherosclerosis,
249: 36–43.
https://doi.org/10.1136/bmj.n71
https://doi.org/10.1016/j.atherosclerosis.2016.02.029
20. Higgins JP, Thomas J, Chandler J, editors. Cochrane
Handbook for Systematic Reviews of Interventions. The 27. Matsuba I, Matsuba R, Ishibashi S, et al., 2018, Effects of a
Cochrane Collaboration; 2011. Available from: https:// novel selective peroxisome proliferator-activated receptor-
[
handbook.cochrane.org Last accessed on 2021 Apr 11]. alpha modulator, pemafibrate, on hepatic and peripheral
glucose uptake in patients with hypertriglyceridemia and
21. Sterne JA, Savović J, Page MJ, et al., 2019, RoB 2: A revised tool insulin resistance. J Diabetes Investig, 9: 1323–1332.
for assessing risk of bias in randomised trials. BMJ, 366: l4898.
https://doi.org/10.1111/jdi.12845
https://doi.org/10.1136/bmj.l4898
28. Ida S, Kaneko R, Murata K, 2019, Efficacy and safety of
22. The Cochrane Collaboration, 2020, Review Manager pemafibrate administration in patients with dyslipidemia:
(RevMan) [Computer Program]. Version 5.4. London: The A systematic review and meta-analysis. Cardiovasc Diabetol,
Cochrane Collaboration. Available from: https://training. 18: 38.
cochrane.org/online-learning/core-software-cochrane-
reviews/revman [Last accessed on 2021 Aug 23]. https://doi.org/10.1186/s12933-019-0845-x
23. Arai H, Yamashita S, Yokote K, et al., 2017, Efficacy and safety 29. Mychaleckyj JC, Craven T, Nayak U, et al., 2012, Reversibility
of K-877, a novel selective peroxisome proliferator-activated of fenofibrate therapy-induced renal function impairment
receptor α modulator (SPPARMα), in combination with in ACCORD type 2 diabetic participants. Diabetes Care,
statin treatment: Two randomised, double-blind, placebo- 35: 1008–1014.
controlled clinical trials in patients with dyslipidaemia. https://doi.org/10.2337/dc11-1811
Atherosclerosis, 261: 144–152.
30. Davis TM, Ting R, Best JD, et al., 2011, Effects of fenofibrate
https://doi.org/10.1016/j.atherosclerosis.2017.03.032 on renal function in patients with type 2 diabetes mellitus:
The fenofibrate intervention and event lowering in diabetes
24. Araki E, Yamashita S, Arai H, et al., 2018, Effects of
pemafibrate, a novel selective PPARα modulator, on lipid (field) study. Diabetologia, 54: 280–290.
and glucose metabolism in patients with type 2 diabetes and https://doi.org/10.1007/s00125-010-1951-1

Volume 1 Issue 2 (2023) 13 https://doi.org/10.36922/bh.1629